Companies › Nelum
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NLM-001 Hedgehog signaling pathway inhibitor | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | – |
| Zalifrelimab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 1 | Pancreatic Ductal Adenocarcinoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04827953 | NLM-001 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2025 |
| NCT04827953 | Zalifrelimab | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.